---

Discussion

Kate Burvish:

The immediate economic case is that federal subsidies should not follow an enrollment that was never validly authorized. CMS estimates that removing these records will return or recover approximately 2.2 billion dollars in advance premium tax credits. It could also make insurers’ risk pools more accurate. But that is a projected recovery, not a realized net saving. We do not yet know how much insurers will actually return, how much could be recovered later through tax reconciliation, or what administrative and downstream costs will follow.

Sofia Jadler:

And CMS’s word—“unauthorized”—is doing important legal work. It does not mean that all 760,000 people committed fraud. The category could include broker misconduct, identity misuse, duplicate coverage, missing information, or a real person enrolled without consent. Those situations may call for different remedies. The public materials do not provide a case-by-case breakdown of the evidence or the reason codes behind the 315,000 cancellations.

Priya Merlan:

That distinction matters medically as well as legally. Someone can be an innocent target of an unauthorized enrollment and still have a genuine prescription, specialist, or treatment plan attached to the policy. We do not know how many of the more than 760,000 people were actively using care when coverage ended. So this is not simply fraud versus no fraud. It is also a question of whether the system can correct an enrollment problem without interrupting care for a real patient.

Red Velhouse:

Sofia, if the government believes an enrollment is unauthorized, what protections should come before coverage is terminated—and what remains unclear about this particular action?

Sofia Jadler:

At minimum, the affected person needs notice that identifies the factual basis for the decision, a meaningful opportunity to respond, and a workable appeal process. Marketplace eligibility decisions generally carry appeal rights, and HealthCare.gov says consumers usually have 90 days from an eligibility notice to appeal. But an appeal right on paper is not the same as uninterrupted coverage. The unresolved questions are whether coverage continues during review, whether claims can be reinstated retroactively, and who bears the cost if the decision is reversed.

Priya Merlan:

For a patient, that procedural gap can become an operational gap very quickly. A canceled eligibility record may affect a prescription, an authorization, a provider network, or a clinic’s willingness to schedule care. We should not imply that every cancellation caused an interruption; the data do not show that. But even a temporary dispute can lead someone to delay treatment or pay out of pocket. Continuity during review is therefore not just a compassionate preference. It is a way to limit medical risk while the facts are being sorted out.

Kate Burvish:

There is a real tradeoff. If every disputed enrollment receives indefinite coverage, the government and insurers may keep paying for people who ultimately prove ineligible. If coverage stops immediately, a legitimate patient can face uncompensated care or a medical crisis that costs more later. The economically sensible design may be a tightly timed bridge during review, with clear standards and clear responsibility for claims—not automatic permanent continuation, but not an administrative cliff either.

Red Velhouse:

The administration says this is not an isolated mistake but a control problem that has been documented for years. What supports that argument, and where does the evidence stop?

Sofia Jadler:

The underlying problem is well supported. The Government Accountability Office, Congress’s auditing arm, identified at least 160,000 applications in plan year 2024 that appeared to involve likely unauthorized agent or broker changes. It also reported roughly 275,000 consumer complaints alleging enrollment or plan changes without consent. But complaints and flagged applications are not the same as proven fraud. CMS is on strongest ground when it says its controls were vulnerable; it is on weaker ground if it treats every indicator as conclusive proof against every individual.

Kate Burvish:

The money explains why those weaknesses matter. GAO reported nearly 124 billion dollars in advance premium tax credits for about 19.5 million enrollees in 2024. That is not a fraud estimate, but it shows the scale of the funds moving through a system with imperfect identity and consent checks. Brokers can benefit from enrollment activity, while the government pays substantial subsidies into a system designed for rapid access. Stronger controls may reduce waste, but they also impose costs on honest brokers and consumers.

Priya Merlan:

And the people who need help navigating that system are not always choosing between a perfect online form and a broker. They may have limited digital access, language barriers, or complicated household circumstances. That does not argue for weak authorization. It argues for authorization that is both stronger and usable. A system can improve its paperwork while making real-world access worse if it assumes everyone has the same time, language skills, and digital tools.

Red Velhouse:

That brings us to the broker response. CMS has announced a temporary moratorium on registering new agents and brokers for the 2027 plan year if they lacked an active 2026 Exchange Agreement. Is that targeted oversight or collective punishment?

Sofia Jadler:

The legal question is not simply whether CMS has tools to oversee brokers; it has administrative mechanisms it may invoke, but the scope of that authority and the proportionality of this particular measure remain contestable. CMS says it has sent termination notices to more than 200 noncompliant agents and brokers. The harder question is whether the moratorium reasonably addresses a demonstrated risk or burdens new brokers without individualized findings. CMS reports that newly registered 2026 brokers had higher rates of unresolved verification problems, but the public fact sheet does not provide all the denominators or methodology. That leaves an obvious argument for anyone challenging the policy: the agency may have identified a risk pattern without yet showing that a six-month restriction is the least burdensome effective response.

Kate Burvish:

Economically, restricting new entrants can reduce improper enrollments, but it can also reduce competition and assistance. If legitimate broker help becomes scarcer, consumers may face higher transaction costs or go without coverage. The policy should therefore be judged by its net effect: not just how many suspicious applications it blocks, but also how many eligible people lose practical access to enrollment assistance.

Red Velhouse:

There is another attribution problem. ACA enrollment fell from 22.1 million in 2025 to 19.2 million in 2026. How much of that decline can we reasonably connect to fraud enforcement?

Kate Burvish:

We should resist a single-cause story. Analysts have attributed much of the decline to the expiration of enhanced subsidies, higher premiums, and nonpayment. The administration emphasizes fraudulent or phantom enrollment. Both forces may be operating, but the available figures do not cleanly separate them. A canceled unauthorized record, a household priced out of coverage, and a legitimate enrollee dropped for documentation problems can all lower the enrollment total while representing very different economic realities.

Sofia Jadler:

That uncertainty also matters for accountability. The broader 2025 Marketplace Integrity and Affordability Rule tightened several eligibility procedures, and a federal court stayed some provisions in City of Columbus v. Kennedy while leaving others operative. But that litigation should not be treated automatically as a ruling on these August 31 cancellations. The specific legal status of the cancellations was not clearly established in the materials available here. Any challenge is more likely to focus on notice, statutory authority, individualized evidence, and whether the remedy matched the alleged violation.

Priya Merlan:

From a health perspective, the next evidence should be more concrete than the headline count. We need to know how many affected people were using coverage, how quickly medications and treatment were restored, and whether patients experienced gaps. A low appeal rate would not necessarily show that the process worked; people may not know how to appeal or may be unable to navigate it. A high reinstatement rate, meanwhile, would suggest that the initial screen was too blunt.

Red Velhouse:

So what should viewers watch next if they want to distinguish effective enforcement from administrative overcorrection?

Kate Burvish:

Watch actual subsidy recoupment and insurer-level effects, not just the projected 2.2 billion dollars. If unauthorized or phantom enrollments were removed, federal outlays and risk pools could improve. If legitimate, low-use enrollees were removed, the remaining pool could become sicker and more expensive. The accounting should include recovered subsidies, administrative costs, uncompensated care, and enrollment changes caused by higher premiums after the enhanced subsidies expired.

Sofia Jadler:

And watch transparency. CMS should publish aggregate information about cancellation reasons, states and insurers involved, broker connections, appeals, and reinstatements. That would not require exposing private records, but it would let outsiders test whether the action was precise. An agency can win the political argument that fraud exists and still lose the legal and institutional argument if affected people cannot understand or challenge the decision.

Red Velhouse:

The central unresolved issue is whether CMS identified unauthorized activity with enough precision to protect taxpayers without cutting legitimate people off from care. The fraud problem is supported by complaints, audits, and weak consent controls; the scale and consequences of this particular cancellation remain less clear. Watch appeal and reinstatement rates, insurer subsidy recoupment, treatment disruptions, legal challenges, the fate of the 419,000 enrollments under review, and whether stronger electronic authorization works during 2027 enrollment. Sources and references for this discussion are available with the episode at Factolio.com.

---

Sources and References

These sources supported the factual material used in this discussion. Factolio’s panel discussion is AI-generated from researched evidence and is written in original language.

1. Centers for Medicare & Medicaid Services — Federal Marketplace (FFE and SBE-FP) Anti-Fraud Actions (PRIMARY)
2. Centers for Medicare & Medicaid Services — CMS to remove Marketplace coverage for more than 760,000 as part of anti-fraud efforts (NEWS)
3. Centers for Medicare & Medicaid Services — CMS Finalizes Major Rule to Lower Individual Health Insurance Premiums for Americans (PRIMARY)
4. Associated Press — Trump administration to remove 760,000 Affordable Care Act enrollees over fraud claims (NEWS)
5. Federal Register — Temporary Moratorium on Certain New Agent and Broker Registrations for Plan Year 2027 (PRIMARY)
6. U.S. Government Accountability Office — Patient Protection and Affordable Care Act: Preliminary Results from Ongoing Review Suggest Fraud Risks in the Advance Premium Tax Credit Persist (PRIMARY)
7. U.S. Government Accountability Office — Health Insurance Marketplaces: CMS Needs Stronger Controls to Prevent Unauthorized Actions by Agents and Brokers (PRIMARY)
8. Associated Press — Millions drop Obamacare health plans after subsidies expire and costs rise (NEWS)
9. Associated Press — Obamacare rolls shrank dramatically in many states over the past year, new federal data shows (NEWS)
10. KFF Health News — Plan-Switching, Sign-Up Impersonations: Obamacare Enrollment Fraud Persists (NEWS)
11. HealthCare.gov — What can I appeal? (PRIMARY)
12. Centers for Medicare & Medicaid Services — Appeals help (PRIMARY)
13. Centers for Medicare & Medicaid Services — CMS Statement on System Changes to Stop Unauthorized Agent and Broker Marketplace Activity (PRIMARY)
14. Centers for Medicare & Medicaid Services — 2025 Marketplace Integrity and Affordability Final Rule (PRIMARY)
15. U.S. District Court for the District of Maryland, summarized case opinion — City of Columbus v. Kennedy (PRIMARY)
16. Georgetown University Health Policy Institute — Marketplace Rules: City of Columbus et al. v. Kennedy (ANALYSIS)